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Hepatocellular carcinoma is one of the most frequently encountered malignancies worldwide. Its asso-
ciation with cirrhosis increases the difﬁculty of diagnosis and therapy. Different approaches, ranging
from medical treatment to highly complex ablative and surgical therapies, including liver resection and
transplantation have signiﬁcantly improved the outcome of this disease.
This article reviews the current diagnostic challenges and the available surveillance and classiﬁcation
protocols. Available therapeutic approaches, indications, contraindications and outcome of liver resec-
tion, liver transplantation, living donor liver transplantation, are outlined in detail. Ablative procedures
and their role and efﬁciency as ‘‘bridging’’ methods to liver transplantation are included in the review.
 2008 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
One of the most intriguing debates among physicians involved
with liver diseases and liver transplantation is the therapy of
hepatocellular carcinoma (HCC). There are about 8500–11,500 new
HCC cases diagnosed in the USA every year. HCC is the third leading
cause of cancer-related deaths1 and has a steep increase in inci-
dence and mortality in the Western world,2 having doubled its
incidence in the United States between 1985 and 1998.3 The fact
that about 95% of cases arise in the complex setting of cirrhosis4
makes the diagnosis of HCC and its therapeutical approach a chal-
lenging and versatile ﬁeld.2. Diagnosis and surveillance
The difﬁculty of management is further enhanced by the
frequently encountered multifocality of the disease as well as by
the imperfection of current imaging techniques in discriminating
the malignant lesions from regenerative nodules. In a recent met-
aanalysis, Colli et al. determined a pooled sensitivity of 60% for
ultrasound studies, 68% for CT studies and 81% for MRI studies in
diagnosing HCC. Lesions larger than 2 cm are more readily diag-
nosed and a typical appearance (rapid contrast uptake during
arterial phase with washout during the venous phase) on CT or MRI
precludes further diagnostic studies. In tumors between 1 and
2 cm, coincident ﬁndings on both CT and MRI are required for
diagnosis. Tumors smaller than 1 cm, being incompletelyCarbondale, IL 62901, USA.
Elsevier Ltd on behalf of Surgical Avascularised, very often elude radiologic diagnosis5 and should be
monitored closely. A biopsy is only required in equivocal situations,
but a negative ﬁnding will be regarded with suspicion, especially in
small tumors. The role of alfa fetoprotein (AFP) in the diagnosis of
HCC is limited and this study is no longer recommended for
surveillance.6 However, values higher than 200 ng/ml are highly
speciﬁc for HCC if found concomitantly with a liver mass.7
Currently, biannual ultrasound surveillance is considered sufﬁcient
for the cirrhotic patient without HCC, but any suspicious lesion should
warrant further investigations until the diagnosis of malignancy is
conﬁrmed or inﬁrmed, and surveillance after a positive diagnosis
should be done more frequent and by high-speciﬁcity studies (CT,
MRI) rather than by ultrasound, to avoid overlooking of further tumor
development. The preoperative staging of the malignant growth is
a very important prognostic factor and is frequently suboptimal.
3. Staging systems
Several staging systems have been developed for HCC.While the
TNM classiﬁcation is still the most popular for its ease of use, the
Barcelona Clinic Liver Cancer (BCLC) approach computes number
and size of lesions, presence of lymph nodes and metastases,
severity of the underlying cirrhosis, portal invasion and patient
performance status into a system that allows the clinician to choose
themost adequate therapyand to accuratelypredict theoutcome for
each stage8 (Fig. 1).
4. Therapeutic approach
One of the key aspects of management of HCC patients is
a multidisciplinary approach. A specialized hepatobiliary andssociates Ltd.
Fig. 1. The Barcelona Clinic Liver Cancer staging protocol. PST¼ performance status test. N¼ nodules. M¼metastases. PEI¼ percutaneous ethanol injection. (From Ref. 8, with
permission.)
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following these patients. The hepatologist and hepatobiliary/
transplant surgeon should work closely with the experienced
interventional radiologist, oncologist and pathologist to optimize
the timing and type of treatment.
The goal of treatment is to remove the malignancy while
preserving liver function. There are two main criteria dictating the
therapeutic approach: the severity of underlying cirrhosis and the
overall tumor burden as evaluated by the number of nodules, their
size and vascular invasion.
The therapeutic armamentarium offers a broad array of possi-
bilities, which can be summarized as:
- liver resection
- ablative procedures – percutaneous ethanol injection (PEI),
radiofrequency ablation (RFA), cryoablation
- transarterial chemoembolization (TACE)
- liver transplantation
- systemic agents (all with limited efﬁcacy) – tamoxifen, doxo-
rubicin, interferon, octreotide, antiandrogens
- selective internal radiation therapy (SIRT) is a novel, promising
therapy featuring intra-arterial administration of microspheres
coated with radioactive agents (Yttrium 90, Iodine 131).4.1. Surgical liver resection
Surgical resections are reserved for non-cirrhotic patients and
cirrhotics with well-preserved liver function and low tumor
extension (ideally single tumor). The results of this therapy are
maximized when performed in experienced centers. The selection
of candidates is of paramount importance for the outcome. Bili-
rubin values of >1.1 mg/dl and portal hypertension with hepatic
vein pressure gradient 10 mmHg were shown to be predictors of
postoperative hepatic decompensation.9 Even if the vein pressuregradient is not measured routinely, other signs of portal hyper-
tension, such as oesophageal varices, ascites, splenomegaly or
thrombocyte count<100,000/mm3 should preclude liver resection.
Under ideal circumstances, a perioperative mortality of less than 3%
and a 5-year survival rate higher than 50% can be achieved.10
One of the important problems after resection is the high
frequency of tumor recurrence (either growth of micrometastases
or de novo tumors), which can be as high as 70% at 5 years and is
frequently multifocal. Repeated resection is feasible in only about
20% of these patients. Therefore, a highly aggressive follow-up
should be recommended, and it might be a wise approach to have
these patients recommended for liver transplantation even after
a ‘‘radical’’ resection.
4.2. Ablative therapies
Ablative therapies are usually reserved for patients that are not
candidates for liver resection, because of amore advanced degree of
liver disease. According to local preferences and expertise, radio-
frequency ablation (percutaneous, laparoscopic or open) and
percutaneous ethanol injection (PEI) are the most frequently used
procedures (Fig. 2). According to the Barcelona staging, they can be
used in patients with early stage disease. The best results are ach-
ieved in liver masses smaller than 3 cm, where the radicality of
these procedures can be compared to that of liver resection.6
Compared to PEI, RFA can achieve a higher percentage of necrosis in
tumors larger than 3 cm11 and, when performed laparoscopically,
RFA can offer access to difﬁcult anatomical sites and completely
destroy the tumor in more than 90% of ablated sites.12,13
4.3. Transarterial chemoembolization
Injection of a chemotherapeutic agent (doxorubicin, cisplatin)
and occlusion of the artery supplying the liver lobe that contains
the mass can be achieved through interventional radiologic
Fig. 2. Ablative therapies for HCC patients on the waiting list.
Milan Criteria (Mazzaferro et al., 1996)
• Single tumor < 5 cm, or
• 2-3 tumors none exceeding 3 cm, and
• no vascular invasion and/or extrahepatic spread
UCSF Criteria (Yao et al., 2001)
• Single tumor < 6.5 cm, or 
• 2-3 lesions, none exceeding 4.5 cm, with total tumor diameter < 8 cm
• no vascular invasion and/or extrahepatic spread
Fig. 3. The ‘‘Milan Criteria’’ deﬁned by Mazzaferro in 1996 deﬁne the tumor load
within which the survival rates are similar to those of patients without malignant
disease. Some institutions like the University of California at San Francisco (UCSF) try
to extend the indications to limits where the survival and recidive rates are still
acceptable.
MELD Score = 0.957 x Loge (creatinine mg/dL) + 0. 378 x Loge (bilirubin mg/dL)
       + 1.120 x Loge (INR) + 0.643
Fig. 4. The Model of End Stage Liver Disease (MELD) equation computes the three
most important predictors of mortality on the waiting list: creatinine, bilirubin and the
International Normalized Ratio (INR) for prothrombin time.
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candidates for resections or ablative therapy, secondary to their
higher tumor load and/or more advanced degree of cirrhosis. The
procedure is inappropriate however for patients with advanced
malignancy or decompensated cirrhosis (Child C or advanced Child
B). Portal vein thrombosis, hepatofugal blood ﬂow, and coagulation
disorders are some of the other contraindications of the procedure.
Careful selection of patients is required to avoid severe complica-
tions such as liver failure.
5. Liver transplantation for hepatocellular carcinoma
As mentioned above, surgical resection and ablative therapies
have signiﬁcant limitations and recurrence rates. The patients that
beneﬁt from these measures are highly selected and must have
good liver reserves and a low tumor burden. Therefore, liver
transplantation has emerged as a viable alternative or rather
a complementary measure that extends the therapeutic arma-
mentarium to patients with more advanced cirrhosis and HCC.
The most ardent problem in liver transplantation is the shortage
of available organs. When deciding the allocation of organs to HCC
patients, the survival chances have to outweigh the risk of dying
from recurrent disease. Overall, an ‘‘acceptable’’ survival rate
should be comparable to that of patients treated for non-malignant
diseases.
5.1. Patient selection
HCC is usually a slow-growing malignancy. However, the fact
that it appears in the cirrhotic patient as well as its tendency to
multifocality and to recurrence after therapy recommend liver
transplantation as a logical way to deal with both malignancy and
liver disease.
In the early 80’s, as soon as liver transplantation became an
accepted standard therapy for end-stage liver disease, the indica-
tion for liver replacement was extended, somehow indiscriminate,
to patients with liver tumors. After initial poor results, the trans-
plant community learned that recurrence and progression of
malignancy are very rapid under immunosuppression and that the
indication for transplantation should be limited to carefully
selected patients. Number and size (>5 cm) of tumors, and vascular
invasion were identiﬁed as poor prognostic factors14 and patients
with extrahepatic disease were excluded from transplantation. In
time, other factors that affect survival and recurrence wereidentiﬁed, such as positive nodes and histologic grading.15 An
accurate preoperative staging seems to have a beneﬁcial effect on
tumor recidive.16
In 1996, Mazzaferro et al. published a landmark study, imposing
the so-called ‘‘Milan Criteria’’. This study showed that patients with
up to 3 tumors, none larger than 3 cm, or 1 tumor 5 cm had an
excellent survival, while patients exceeding these criteria had
a signiﬁcantly worse outcome.17 Even though data from the
University of California at San Francisco (UCSF) and from theMount
Sinai Medical Center in New York showed that acceptable survival
and disease-free survival rates can be achieved in patients with
slightly higher tumor load (Fig. 3),18,19 there is still not enough
information to impose the routine transplantation of patients with
higher tumor burden. Multimodal approaches with preoperative
downstaging via TACE and postoperative chemotherapy seem to
beneﬁt certain patients with tumor extension beyond Milan
criteria.19
5.2. Organ allocation
Patients with HCC frequently have a relatively well-preserved
liver function, even if this remaining function is not always enough
to qualify them for resection. Classically, they have longer waiting
times and a higher chance of being removed from the transplant list
due to progressive disease. Yao et al. found a 25% yearly drop-out
rate from the waiting list in these patients.20
In 2002, the United Network for Organ Sharing (UNOS) intro-
duced the Model for End Stage Liver Disease (MELD) score to
prioritize patients awaiting liver transplantation. This is a score that
accurately predicts the 90 days mortality risk of patients while on
thewaiting list (Fig. 4). Recognizing that the patients with HCC have
a higher mortality risk than predicted by their MELD score, the
current UNOS policy exceptionally attributes a MELD score of 22
(equivalent to a 15% mortality risk on the waiting list) to HCC
patients that have solitary tumors between 2 and 5 cm or 2–3
tumors, none larger than 3 cm. This score allows transplantation
within 6 months in most centers. The score can be upgraded every
three months with an additional equivalent of 10% mortality risk.
Patients with HCC smaller than 2 cm do not receive exceptional
MELD scores after it has been observed that about 30% of these
Fig. 5. Patient survival rates for transplanted patients with and without HCC.
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in the explanted livers. The implementation of this policy led to
a signiﬁcant decrease of the waiting time and waiting list mortality
of HCC patients and to a signiﬁcant increase in the number of
transplanted HCC patients.21
In Europe, a new Eurotransplant policy implemented in 2005
allows HCC patients that fall within Milan criteria and have already
been on the waiting list for one year to be upgraded to priority
status T2 (equivalent to Child C cirrhosis), whereby most patients
are transplanted within 6 months.
5.3. ‘‘Bridging’’ therapies
The progression of hepatocellular carcinoma can be sometimes
unpredictable, and patients that seem ideal candidates for liver
transplantation can present a few months later with multicentric
progression of their malignancy. The time spent on the waiting list
seems to be a very important predictor of tumor progression and
drop-out from the waiting list. Therefore, before the MELD era,
treating these patients with ablative procedures or TACE was
a rational approach to maintain them in an active transplant status.
There are no conclusive studies to attest the superiority of one or
another ablative procedure or TACE, but there is a general
consensus that ‘‘bridging’’ procedures played an important role in
avoiding the drop-out from the waiting list.11,12,22–27 Under current
conditions, when HCC patients are transplanted with priority and
have a signiﬁcant shorter waiting time, the role of the bridging
procedures needs to be re-evaluated. One argument in favour of
continuing to treat the tumors before transplantation is that the
waiting time can be prolonged by several other independent factors
(medical or social) which can repeal the advantage of the MELD
exception. Also, there is clearly a role for these procedures in
‘‘downstaging’’ lesions that otherwise would exceed Milan criteria
as well as in patients with borderline large tumor load that would
otherwise be at risk for drop-out from the waiting list.
5.4. Outcome
When offering liver transplantation to HCC patients, survival
rates comparable to those of patients transplanted with non-
malignant diseases should be obtained. Failure to do so attracts the
anthem of wasting valuable donor organs on patients that do not
achieve sufﬁcient survival beneﬁt from transplantation. Survival in
these patients is directly linked to recidive of malignancy, which is
more rapid and aggressive under immunosuppression. Several
factors, mentioned earlier in this paper, were identiﬁed as predic-
tors of recurrence andmortality. Among them, the number and size
of tumors seem to be the most amenable to routine use and are
incorporated in the various policies of organ allocation and patient
selection. While outcome in untreated HCC is almost uniformly
fatal, the overall 3-year survival rate after liver transplantation in
patients that fall within the Milan criteria is expected to be 60–70%.
According to the Scientiﬁc Registry of Transplant Recipients (SRTR)
2008 report,28 the 1- and 3-year survival for patients transplanted
with HCC is signiﬁcantly lower than the survival rate for trans-
plantation for other diagnoses (Fig. 5). Even though it is considered
that patients with higher tumor load tend to do poorer, some
authors have found comparable survival rates in patients with pT2
tumors (corresponding to the Milan criteria) and patients with pT3
tumors challenging the Milan criteria and the current allocation
system as being to restrictive. As mentioned earlier, several leading
centers have proposed less restrictive selection criteria, and this
seems to be sustained by more recent data published by Onaca
et al.29 These authors provide data from the International Registry
of Hepatic Tumors in Liver Transplantation showing encouragingresults from this large database in patients transplanted for HCC
between 1992 and 2005 (Fig. 6).
Recently, it was suggested that genotype analysis might identify
gene alterations within the tumoral tissue that would predict post-
transplant tumor recurrence.30 Othermarkers, such as the presence
of AFPmRNA expressing cells in the peripheral blood are also under
evaluation for their predictive power in regard to tumor recur-
rence.31 Identifying such predictors might allow a more accurate
selection of transplant candidates among patients with hepato-
cellular carcinoma.
All these results should be interpreted keeping in mind that the
outcome of this patient population depends on several other
factors. The smaller degree of liver disease is a favourable prog-
nostic sign. Burroughs et al. found that HCC was a predictor of
favourable outcome within the ﬁrst three months; however, this
advantage is not maintained on medium and long terms.32 On the
other hand, a quite frequent policy is to use organs from high-risk
donors to transplant these patients; while this may reduce the
mortality and drop-out rate on the waiting list, it also affects post-
transplantation outcome.
Chemotherapy delivered intra- and postoperative (with Doxo-
rubicin being the most popular agent) does not seem to improve
outcome.33 The immunosuppression regimens used after trans-
plantation may have a certain importance, with the anti-
proliferative effect of sirolimus being postulated. Sirolimus in HCC
patients has been used in practice in several centers around the
world, based on clinical observations and favourable in vitro effects
and is currently under investigation by randomized studies (the
SILVER Study in Europe).5.5. Living donor liver transplantation (LDLT) for HCC
LDLT emerged as a way to expand the donor pool, offering
a chance to be transplanted to HCC patients that would not meet
transplantation criteria based on their underlying liver disease.
LDLT also decreases the projected waiting time for the potential
recipient, increasing their chances to beneﬁt from their transplant.
The main issue with LDLT is the mortality and morbidity that may
occur in the donor even under the strictest precautions. Based on
life expectancy and cost-effectiveness analysis, LDLT is warranted if
the waiting time for a liver graft is expected to exceed 7 months.34
Approximately 16–18% of the total number of cadaveric liver
transplants in the USA go to HCC candidates. Additional 2–4% are
LDLT.28 However, in areas of the world where cadaveric organ
donation is not a routine practice, the procedure is highly popular.
Fig. 6. Recurrence-free survival rate according to tumor load in HCC patients. Data from the International Registry of Hepatic Tumors in Liver Transplantation. From Ref. 29, with
permission.
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receiving a living donor transplant when compared to cadaveric
donation, and there are signiﬁcant differences between the
outcome of LDLT in HCC and other diagnoses (Fig. 7).Fig. 7. Adjusted 3-year patient survival of LDLT and dAnother controversial issue is LDLT for patients that exceed
Milan criteria and therefore are excluded from the usual HCC
exception. Donation in this situation is an act of altruism and one of
exceptional emotional intensity. The potential recipients haveeceased donor transplant recipients by diagnosis.
A.P. Martin / International Journal of Surgery 7 (2009) 324–329 329a limited life expectancy and LDLT is virtually their only survival
chance, making the decision more difﬁcult. The Milan criteria
largely maintain their prognostic accuracy in LDLT, although
patients with higher tumor load can be transplanted with
remarkable beneﬁt. Japanese authors35 show a 3-year survival and
disease-free survival of 78.7% and 79.1% respectively in patients
within Milan criteria. But even when these parameters were
exceeded, 60% of patients were alive at 3 years. Survival and
disease-free survival rates were 60.4% and 52.6% in these patients.
Considering these results as being acceptable or not is rather
a matter of experience and attitude of each transplant center and
they have to be extensively discussedwith the potential donors and
recipients.
6. Conclusion
Liver transplantation has established its role in treating hepa-
tocellular carcinoma. It is the only viable therapeutic alternative for
patients with non-resectable disease. While priority criteria
imposed by UNOS represent a signiﬁcant step towards preventing
drop-out and mortality while on the waiting list, setting the limits
of transplantability is still an active, challenging ﬁeld. The Milan
criteria imposed in 1995 seem to maintain their prognostic value,
but means to allow selection of those patients whowould still have
a favourable outcome beyond these limits are actively searched.
The role of ‘‘bridging’’ therapies and of LDLT in the setting of recent
changes in the organ allocation policy has to be re-evaluated.
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